Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
出版年份 2014 全文链接
标题
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 25, Issue 2, Pages 529-536
出版商
Oxford University Press (OUP)
发表日期
2014-01-14
DOI
10.1093/annonc/mdt552
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
- (2011) G. R. Blumenschein Jr et al. ANNALS OF ONCOLOGY
- INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
- (2011) Yi-Long Wu et al. BMC CANCER
- A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer
- (2011) Xin Zhao et al. INVESTIGATIONAL NEW DRUGS
- Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (SAiL) Study
- (2011) Chun-Ming Tsai et al. Journal of Thoracic Oncology
- Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer
- (2011) Isamu Okamoto et al. Journal of Thoracic Oncology
- Use of non-anthracycline regimens in early stage breast cancer in Australia
- (2010) Richard H DE BOER et al. Asia-Pacific Journal of Clinical Oncology
- Lung Cancer Working Group Report
- (2010) N. Saijo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status
- (2010) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
- (2010) Myung-Ju Ahn et al. Journal of Thoracic Oncology
- Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
- (2010) G. Scagliotti et al. ONCOLOGIST
- Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer
- (2009) G. R. Blumenschein et al. CLINICAL CANCER RESEARCH
- Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
- (2009) David R. Gandara et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapies for non-small cell lung cancer
- (2009) Wolfram C.M. Dempke et al. LUNG CANCER
- Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study
- (2008) Neal D Freedman et al. LANCET ONCOLOGY
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More